Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Grivas Spotlights Advances With Immunotherapy-Based Approaches in Urothelial Cancer

May 14th 2024

Petros Grivas, MD, PhD, discusses the significance of the phase 3 JAVELIN Bladder 100, EV-302, and CheckMate 901 trials in urothelial cancer.

Dr Bellmunt on Enfortumab Vedotin/Pembrolizumab in the Community Setting for Urothelial Carcinoma

May 13th 2024

Joaquim Bellmunt, MD, PhD, discusses treatment with enfortumab vedotin plus pembrolizumab in patients with urothelial carcinoma in the community setting.

EV-302 Trial Ushers in Era of Novel Combos in First-Line Metastatic Urothelial Cancer

May 10th 2024

Joaquim Bellmunt, MD, PhD, discusses the impact of enfortumab vedotin plus pembrolizumab on the treatment paradigm in first-line urothelial cancer.

Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist

May 6th 2024

No significant difference in time to treatment was found between White and Black patients with bladder cancer, but there remained a difference in treatment outcomes.

Dr Siefker-Radtke on the Safety of Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

May 6th 2024

Arlene O. Siefker-Radtke, MD, discusses toxicities associated with enfortumab vedotin plus pembrolizumab in patients with bladder cancer.

TAR-210 Demonstrates Preliminary Efficacy in FGFR-Altered Non–Muscle-Invasive Bladder Cancer

May 5th 2024

TAR-210 was safe and showed promising clinical activity in patients with FGFR-altered high- and intermediate-risk non–muscle-invasive bladder cancer.

Dr Kutikov on Therapeutic Approaches in Urothelial Cancer Requiring Cystectomy

May 5th 2024

Alexander Kutikov, MD, FACS, discusses treatment options for patients with urothelial cancer requiring cystectomy.

Dr Li on the Rationale of the MoonRISe-1 Trial in NMIBC

May 5th 2024

Roger Li, MD, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820).

Nadofaragene Firadenovec Demonstrates Durable 5-Year Activity in NMIBC

May 5th 2024

Nadofaragene firadenovec led to durable antitumor activity in BCG-unresponsive NMIBC either with CIS or papillary disease, according to 5-year data from the phase 3 Study CS-003.

UGN-102 With/Without TURBT Produces Similar DOR and DFS in Newly Diagnosed and Recurrent NMIBC

May 5th 2024

UGN-102 with/without TURBT displayed meaningful and similar DFS and DOR rates in newly diagnosed and recurrent low-grade intermediate-risk NMIBC.

Dr Meeks on Harnessing Innovation in Bladder Cancer

May 4th 2024

Joshua J. Meeks, MD, PhD, discusses effectively implementing recent therapeutic advances across the disease continuum of bladder cancer.

Dr Shore on the Importance of a Multidisciplinary Team in Urologic Oncology

May 3rd 2024

Neal Shore, MD, FACS, discusses the importance of a multidisciplinary team in light of recent developments in urologic oncology.

Extended Lymphadenectomy Shows No DFS, OS Benefit During Radical Cystectomy in Urothelial Cancer

May 3rd 2024

Concurrent radical cystectomy and extended lymph node dissection did not show benefit vs standard lymph node dissection in muscle invasive urothelial cancer.

TAR-200 Leads to Durable Responses in Bacillus Calmette–Guérin-Unresponsive NMIBC

May 3rd 2024

TAR-200 displayed a high complete response rate in Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer.

Dr Tyson on the Phase 3 BOND-003 Trial in BCG-Unresponsive NMIBC With CIS

May 3rd 2024

Mark D. Tyson, II, MD, MPH, discusses findings from the phase 3 BOND-003 trial in BCG-unresponsive non–muscle-invasive bladder cancer with CIS.

Dr Rosenberg on Toxicity Management With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

May 3rd 2024

Jonathan E. Rosenberg, MD, discusses toxicity management when administering enfortumab vedotin plus pembrolizumab in urothelial cancer.

Cretostimogene Monotherapy Elicits Durable CRs in High-Risk NMIBC

May 3rd 2024

Cretostimogene grenadenorepvec elicited durable responses in high-risk BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ.

Dr Bellmunt on the Impact of Treatment With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

May 2nd 2024

Joaquim Bellmunt, MD, PhD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the urothelial cancer treatment paradigm.

ADCs and Immunotherapy Broaden the Bladder Cancer Treatment Paradigm

May 2nd 2024

Jonathan E. Rosenberg, MD, discusses how recent FDA approvals have revolutionized the treatment paradigm for locally advanced or metastatic bladder cancer.

N-803/BCG Approval Signals Paradigm Shift in Management of BCG-Unresponsive NMIBC

May 1st 2024

Karim Chamie, MD, discusses the significance of the FDA approval of N-803 plus BCG in BCG-unresponsive non–muscle invasive bladder cancer.